الفهرس 
Prognostic value of metformin in locally advanced irresectable non small cell lung cancer patients
النتائج والسمات التنبؤية لعقار الميتفورمين فى مرضي المصابين بسرطان الرئة المتقدم محليا والغير قابل للاستئصالOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Locally advanced NSCLC is frequently inoperable and treated with combined chemoradiotherapy with poor outcomes due to high resistance to chemotherapy. Metformin, a first line anti diabetic medication, was found to have an anti-tumor effect. The study is a prospective study evaluating the efficacy and toxicity of adding metformin to concomitant chemo-radiotherapy using platinum based chemotherapy (paclitaxel 45mg\m2,carboplatin AUC 2 weekly with thoracic radiation of 60 Gy in 30 fractions over 6 weeks in locally advanced irresectable non small cell lung cancer patients. We enrolled 30 patients of locally advanced irresectable lung cancer patients and divided into two groups . group A included 15 patients received concomitant chemo-radiotherapy with metformin and group B received concomitant chemo-radiotherapy without metformin and concluded no statistically significant difference were found between the two groups as regard clinical response and over all clinical benefit and was tolerable. Adding metformin to concurrent in locally advanced irresectable NSCLC patients improved the PFS but did not effect the OS at one year follow up